Immune cell recruitment and cell-based system for cancer therapy.
Immune cells, such as cytotoxic T lymphocytes, natural killer cells, B cells, and dendritic cells, have a central role in cancer immunotherapy. Conventional studies of cancer immunotherapy have focused mainly on the search for an efficient means to prime/activate tumor-associated antigen-specific immunity. A systematic understanding of the molecular basis of the trafficking and biodistribution of immune cells, however, is important for the development of more efficacious cancer immunotherapies. It is well established that the basis and premise of immunotherapy is the accumulation of effective immune cells in tumor tissues. Therefore, it is crucial to control the distribution of immune cells to optimize cancer immunotherapy. Recent characterization of various chemokines and chemokine receptors in the immune system has increased our knowledge of the regulatory mechanisms of the immune response and tolerance based on immune cell localization. Here, we review the immune cell recruitment and cell-based systems that can potentially control the systemic pharmacokinetics of immune cells and, in particular, focus on cell migrating molecules, i.e., chemokines, and their receptors, and their use in cancer immunotherapy.
Gao
Jian-Qing
JQ
College of Pharmaceutical Sciences, Zhejiang University, 388 Yuhangtang Road, Hangzhou 310058, People's Republic of China. gaojianqing1029@yahoo.com.cn
Okada
Naoki
N
Mayumi
Tadanori
T
Nakagawa
Shinsaku
S
D019264:Adoptive Transfer / Q000009:adverse effects; D000818:Animals; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D002633:Chemotaxis; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D015316:Genetic Therapy / Q000009:adverse effects; D005822:Genetic Vectors; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology; D019707:Receptors, Chemokine / Q000378:metabolism; D016896:Treatment Outcome
D018925:Chemokines; D019707:Receptors, Chemokine